PMID- 38343062
OWN - NLM
STAT- MEDLINE
DCOM- 20240319
LR  - 20240319
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 99
IP  - 4
DP  - 2024 Apr
TI  - Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A 
      phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once 
      daily (QD) in patients with myelofibrosis.
PG  - 774-779
LID - 10.1002/ajh.27245 [doi]
AB  - Jaktinib, a novel JAK and ACVR1 inhibitor, has exhibited promising results in 
      treating patients with myelofibrosis (MF). ZGJAK002 is a Phase 2 trial aimed to 
      assess the efficacy and safety of jaktinib 100 mg BID (N = 66) and 200 mg QD 
      (N = 52) in JAK inhibitor-naive patients with intermediate- or high-risk MF. We 
      herein present the long-term data with a median follow-up of 30.7 months. At data 
      cutoff, 30.3% of patients in 100 mg BID and 28.8% in 200 mg QD were still 
      continuing their treatment. The 100 mg BID group displayed a numerically higher 
      best spleen response compared with the 200 mg QD group (69.7% vs. 46.2%), with 
      50.4% from the BID and 51.2% from the QD group maintaining spleen responses over 
      120 weeks. The 36-month survival rates were 78.2% in BID and 73.6% in QD group. 
      The tolerability of jaktinib remained well, and common grade >/=3 adverse drug 
      reactions included anemia (15.2% vs. 21.2%), thrombocytopenia (15.2% vs. 11.5%), 
      and infectious pneumonia (10.6% vs. 1.9%) in BID and QD groups, respectively. By 
      comparing the two groups, the incidence of adverse events (AEs) were similar, 
      except for drug-related serious AEs (24.2% vs. 9.6%) and AEs leading to treatment 
      discontinuation (15.2% vs. 7.7%), which were higher in BID group. The percentages 
      of AEs resulting in death were comparable, with 6.1% in BID and 5.8% in QD group. 
      These analyses further support the long-term durable efficacy and acceptable 
      safety of jaktinib at 100 mg BID and 200 mg QD doses for treating MF.
CI  - (c) 2024 Wiley Periodicals LLC.
FAU - Zhang, Yi
AU  - Zhang Y
AUID- ORCID: 0000-0003-3625-2288
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, People's Republic of China.
FAU - Zhou, Hu
AU  - Zhou H
AD  - Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, People's Republic of China.
FAU - Jiang, Zhongxing
AU  - Jiang Z
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, People's Republic of China.
FAU - Wu, Dengshu
AU  - Wu D
AD  - Department of Hematology, Xiangya Hospital, Central South University, Changsha, 
      People's Republic of China.
FAU - Zhuang, Junling
AU  - Zhuang J
AUID- ORCID: 0000-0002-1228-0551
AD  - Department of Hematology, Peking Union Medical College Hospital (Dongdan Campus), 
      Beijing, People's Republic of China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Hematology, Cancer Center, The First Hospital of Jilin University, 
      Changchun, People's Republic of China.
FAU - Jiang, Qian
AU  - Jiang Q
AUID- ORCID: 0000-0001-7131-0522
AD  - National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell, Peking University Institute of Hematology, Beijing, 
      People's Republic of China.
FAU - Wang, Xiuli
AU  - Wang X
AD  - Department of Oncology Hematology, The Second Hospital of Jilin University, 
      Changchun, People's Republic of China.
FAU - Huang, Jinwen
AU  - Huang J
AD  - Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School 
      of Medicine, Hangzhou, People's Republic of China.
FAU - Zhu, Huanling
AU  - Zhu H
AUID- ORCID: 0000-0002-5226-3828
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Yang, Linhua
AU  - Yang L
AD  - Department of Hematology, The Second Hospital of Shanxi Medical University, 
      Taiyuan, People's Republic of China.
FAU - Du, Xin
AU  - Du X
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, People's Republic of China.
FAU - Li, Fei
AU  - Li F
AD  - Department of Hematology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, People's Republic of China.
FAU - Xia, Ruixiang
AU  - Xia R
AD  - Department of Hematology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, People's Republic of China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - Department of Hematology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu, People's Republic of China.
FAU - Hu, Jianda
AU  - Hu J
AUID- ORCID: 0000-0002-4438-2544
AD  - Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, 
      People's Republic of China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Hematopathology, The First Hospital of China Medical University, 
      Shenyang, People's Republic of China.
FAU - Hu, Yu
AU  - Hu Y
AUID- ORCID: 0000-0002-2815-4568
AD  - Department of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, People's Republic of China.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Hematology, Third Xiangya Hospital of Central South University, 
      Changsha, People's Republic of China.
FAU - Jin, Chenghao
AU  - Jin C
AD  - Department of Hematology, Jiangxi Provincial People's Hospital, Nanchang, 
      People's Republic of China.
FAU - Sun, Kai
AU  - Sun K
AD  - Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, People's 
      Republic of China.
FAU - Zhou, Zeping
AU  - Zhou Z
AD  - Department of Hematology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, People's Republic of China.
FAU - Wu, Liqing
AU  - Wu L
AD  - Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, People's Republic of China.
FAU - Yin, Hewen
AU  - Yin H
AD  - Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, People's Republic of China.
FAU - Suo, Shanshan
AU  - Suo S
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, People's Republic of China.
FAU - Yu, Wenjuan
AU  - Yu W
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, People's Republic of China.
FAU - Jin, Jie
AU  - Jin J
AUID- ORCID: 0000-0002-8166-9915
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, People's Republic of China.
LA  - eng
GR  - Suzhou Zelgen Biopharmaceuticals Co., Ltd/
GR  - 2021C03123/Key Research and Development Program of Zhejiang Province/
GR  - 82 100 159/The National Natural Science Foundation of China/
PT  - Clinical Trial, Phase II
PT  - Letter
DEP - 20240211
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
SB  - IM
MH  - Humans
MH  - Follow-Up Studies
MH  - *Primary Myelofibrosis/drug therapy
MH  - Treatment Outcome
EDAT- 2024/02/12 15:43
MHDA- 2024/03/19 06:44
CRDT- 2024/02/12 00:44
PHST- 2024/01/17 00:00 [revised]
PHST- 2023/12/21 00:00 [received]
PHST- 2024/01/19 00:00 [accepted]
PHST- 2024/03/19 06:44 [medline]
PHST- 2024/02/12 15:43 [pubmed]
PHST- 2024/02/12 00:44 [entrez]
AID - 10.1002/ajh.27245 [doi]
PST - ppublish
SO  - Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11.